MX2021009717A - Sulfonamidas biciclicas. - Google Patents

Sulfonamidas biciclicas.

Info

Publication number
MX2021009717A
MX2021009717A MX2021009717A MX2021009717A MX2021009717A MX 2021009717 A MX2021009717 A MX 2021009717A MX 2021009717 A MX2021009717 A MX 2021009717A MX 2021009717 A MX2021009717 A MX 2021009717A MX 2021009717 A MX2021009717 A MX 2021009717A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
formulae
foregoing
methods
acceptable salts
Prior art date
Application number
MX2021009717A
Other languages
English (en)
Spanish (es)
Inventor
David Bernard Smith
Leonid Beigelman
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of MX2021009717A publication Critical patent/MX2021009717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021009717A 2019-02-14 2020-02-12 Sulfonamidas biciclicas. MX2021009717A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805725P 2019-02-14 2019-02-14
PCT/US2020/017974 WO2020167984A1 (en) 2019-02-14 2020-02-12 Bicyclic sulfonamides

Publications (1)

Publication Number Publication Date
MX2021009717A true MX2021009717A (es) 2021-09-14

Family

ID=72045615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009717A MX2021009717A (es) 2019-02-14 2020-02-12 Sulfonamidas biciclicas.

Country Status (13)

Country Link
US (1) US11033556B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022519764A (cg-RX-API-DMAC7.html)
KR (1) KR20210126636A (cg-RX-API-DMAC7.html)
CN (1) CN113423712A (cg-RX-API-DMAC7.html)
AU (1) AU2020221839B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015864A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128061A1 (cg-RX-API-DMAC7.html)
IL (1) IL284940A (cg-RX-API-DMAC7.html)
MX (1) MX2021009717A (cg-RX-API-DMAC7.html)
SG (1) SG11202108835SA (cg-RX-API-DMAC7.html)
TW (1) TW202045516A (cg-RX-API-DMAC7.html)
WO (1) WO2020167984A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220024192A (ko) 2019-05-31 2022-03-03 알리고스 테라퓨틱스 인코포레이티드 변형된 갭머 올리고뉴클레오타이드 및 사용 방법
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
KR20240099159A (ko) 2021-09-08 2024-06-28 알리고스 테라퓨틱스 인코포레이티드 변형된 짧은 간섭 핵산(sina) 분자 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
JP2022519764A (ja) 2022-03-24
TW202045516A (zh) 2020-12-16
AU2020221839B2 (en) 2024-09-12
SG11202108835SA (en) 2021-09-29
KR20210126636A (ko) 2021-10-20
EP3924357A4 (en) 2023-02-22
WO2020167984A1 (en) 2020-08-20
CN113423712A (zh) 2021-09-21
US20200345749A1 (en) 2020-11-05
AU2020221839A1 (en) 2021-08-19
BR112021015864A2 (pt) 2021-10-05
IL284940A (en) 2021-09-30
US11033556B2 (en) 2021-06-15
CA3128061A1 (en) 2020-08-20
EP3924357A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
MX2024000299A (es) Compuestos antivirales.
PH12021552482A1 (en) Compounds targeting prmt5
ZA202206923B (en) New methylquinazolinone derivatives
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12021552513A1 (en) Pyrrole compounds
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2021007247A (es) Derivados de rapamicina.
PH12021552953A1 (en) Tricyclic compounds
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
MX2021007258A (es) Composiciones de esparsentan amorfas.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
ZA202204442B (en) Salt forms of a complement component c5a receptor
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX379576B (es) Derivados de azetidina
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
EA202190458A1 (ru) Составы, содержащие дендример
WO2021015294A3 (en) Combination therapy for cancer treatment
MX2022007625A (es) Combinaciones.
EA202192382A1 (ru) Соединения, нацеленные на prmt5